文献速递细菌感染、耐药与抗菌药物医院感染防控

多重耐药菌状态与晚期癌症姑息治疗患者临终照护质量的关联:全国数据链接的回顾性队列研究

Association between multidrug-resistant organism status and quality of end-of-life care in patients with advanced cancer referred to palliative care: a retrospective cohort study with nationwide data linkage.
PubMed 文献 · Clin Microbiol Infect · 2025-12-02

该回顾性队列研究纳入2018年1月至2022年12月韩国某三级医院转诊姑息治疗的晚期癌症患者共6151例,其中523例(8.5%)检出MDRO。MDRO状态与社区安宁疗护使用减少、三级医院死亡及侵入性干预增加相关,提示MDRO可能降低临终照护质量。

要点

  • 晚期癌症姑息治疗患者中MDRO检出率为8.5%(523/6151)。
  • MDRO状态与住院安宁疗护(aOR 0.56)和居家安宁疗护(aOR 0.39)使用减少相关。
  • MDRO状态与三级医院死亡(aOR 1.74)、ICU入住(aOR 2.18)及肾脏替代治疗(aOR 1.63)增加相关。

核心结论

  • MDRO状态可能与晚期癌症姑息治疗患者临终照护质量较低相关,表现为社区安宁疗护可及性降低和更积极的干预。

研究设计与样本

  • 回顾性队列研究,纳入2018年1月至2022年12月韩国某三级医院转诊姑息治疗的晚期癌症患者6151例,均于2023年6月前死亡,临床数据与全国医保理赔数据链接。

主要发现

  • 6151例患者中523例(8.5%)检出MDRO。
  • MDRO组住院安宁疗护使用率为24.1% vs 37.8%(aOR 0.56,95%CI 0.45-0.70,p<0.001),居家安宁疗护为2.7% vs 7.4%(aOR 0.39,95%CI 0.22-0.67,p=0.001)。
  • MDRO组三级医院死亡更频繁(aOR 1.74,95%CI 1.43-2.12,p<0.001),ICU入住(aOR 2.18,95%CI 1.51-3.16,p<0.001)和肾脏替代治疗(aOR 1.63,95%CI 1.03-2.60,p=0.039)更多。
  • MDRO组在生命最后6个月的医疗费用持续更高。

临床怎么用

  • 对转诊姑息治疗的晚期癌症患者应评估MDRO状态,并据此规划感染防控与安宁疗护衔接。
  • 需制定支持高质量、以患者为中心的临终照护的感染控制策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Multidrug-resistant organisms (MDROs) are becoming increasingly prevalent among patients with advanced cancer referred for palliative care (PC), and may adversely impact the quality of end-of-life care. METHODS: We conducted a retrospective cohort study of patients with advanced cancer who were referred for PC at a tertiary hospital in South Korea between January 2018 and December 2022 and died before June 2023. Clinical data of patients were linked to nationwide health insurance claims data, enabling comprehensive longitudinal assessment of the end-of-life trajectory beyond a single institution. MDRO status was defined as the detection of resistant organisms in any clinical specimen at the time the patient was referred for PC. Outcomes included utilization of hospice services, in-hospital death at tertiary care centres, receipt of aggressive end-of-life interventions, and total medical costs. Adjusted associations were estimated using logistic and γ regression models. RESULTS: Among 6151 patients, 523 (8.5%) had MDROs detected. MDRO status was associated with significantly lower use of community-based hospice care, including inpatient hospice (24.1% vs. 37.8%; adjusted odd ratios [aOR], 0.56, 95% CI, 0.45-0.70; p < 0.001) and home hospice (2.7% vs. 7.4%; aOR, 0.39, 95% CI, 0.22-0.67; p = 0.001). It was also associated with more frequent deaths in tertiary hospitals (aOR, 1.74; 95% CI, 1.43-2.12, p < 0.001), and higher intensive care unit admissions (aOR, 2.18; 95% CI, 1.51-3.16, p < 0.001) and renal replacement therapy (aOR, 1.63; 95% CI, 1.03-2.60, p = 0.039). The medical costs were consistently higher in the MDRO group throughout the last 6 months of life. CONCLUSIONS: MDRO status could be associated with lower quality of end-of-life care, including reduced access to community-based hospice and more aggressive interventions, in patients with advanced cancer referred for PC. These findings underscore the need for infection control strategies that support high-quality, patient-centred care near the end-of-life.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Kim JH, Yu J, Lee W, et al. Association between multidrug-resistant organism status and quality of end-of-life care in patients with advanced cancer referred to palliative care: a retrospective cohort study with nationwide data linkage. Clin Microbiol Infect. 2025. PMID: 41344571. doi:10.1016/j.cmi.2025.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。